Shanxi Zhendong PharmaceuticalLtd Dirección

Dirección controles de criterios 3/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Lianmin Yang

Chief Executive Officer (CEO)

CN¥678.5k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	2.5yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.5yrs
Promedio de permanencia en la Junta Directiva	5.9yrs

Actualizaciones recientes de la dirección

Recent updates

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Mar 07

CEO

Lianmin Yang (61 yo)

2.5yrs

Permanencia

CN¥678,500

Compensación

Mr. Lianmin Yang is President of Shanxi Zhendong Pharmaceutical Co.,Ltd from December 02, 2021 and had been its Deputy General Manager since April 24, 2021 and serves as its Director. He has M.B.A. from Ch...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Lianmin Yang	President & Director	2.5yrs	CN¥678.50k	sin datos
Changlu Liu	Head of Accounting & CFO	5.7yrs	CN¥375.40k	sin datos
Zheyu Wang	VP & Secretary of the Board of Director	1.1yrs	CN¥521.50k	sin datos

2.5yrs

Permanencia media

38yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 300158 se considera experimentado (2.4 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Lianmin Yang	President & Director	no data	CN¥678.50k	sin datos
Anping Li	Chairman	15.5yrs	CN¥1.08m	0.23% CN¥ 9.1m
Zhi Xiang Jin	Supervisor	12.5yrs	sin datos	0.075% CN¥ 3.0m
Ren Hu Li	Chairman of the Supervisory Board	15.5yrs	sin datos	0.082% CN¥ 3.3m
Bin Wu	Independent Director	1.2yrs	CN¥52.10k	sin datos
Rong Fan	Independent Director	2.8yrs	CN¥83.30k	sin datos
Zhimin Wang	Director	15.5yrs	CN¥83.30k	sin datos
Jing Li	Director	5.9yrs	CN¥694.70k	sin datos
Genwang Xu	Supervisor	5.9yrs	sin datos	sin datos
Kun Li	Director	2.2yrs	CN¥688.30k	sin datos
Lina Jin	Independent Director	less than a year	sin datos	sin datos
Wanliang Lv	Independent Director	less than a year	sin datos	sin datos

5.9yrs

Permanencia media

61yo

Promedio de edad

Junta con experiencia: La junta directiva de 300158 se considera experimentada (5.8 años de antigüedad promedio).

Shanxi Zhendong PharmaceuticalLtd Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2022

Recent updates

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.043 loss per share (vs CN¥0.05 loss in FY 2022)

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) Surges 31% Yet Its Low P/S Is No Reason For Excitement

Now 20% undervalued

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: CN¥0.018 loss per share (vs CN¥0 in 3Q 2022)

Now 21% undervalued after recent price drop

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.015 in 2Q 2022)

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥2.55 profit in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.015 (vs CN¥0.12 in 2Q 2021)

Upcoming dividend of CN¥2.70 per share

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022

No independent directors

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan

Investor sentiment deteriorated over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2022

Shanxi Zhendong Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.087 in 3Q 2020)

Investor sentiment deteriorated over the past week

FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) for CNY 5.8 billion.

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.055 in 2Q 2020)

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Final Profit for 2020

Shanxi Zhendong Pharmaceutical Co.,Ltd Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.14 in FY 2019)

New 90-day low: CN¥4.39

Investor sentiment deteriorated over the past week

New 90-day low: CN¥5.46

New 90-day low: CN¥5.73

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q3, 2020 Results on Oct 27, 2020

New 90-day high - CN¥6.39

New 90-day high - CN¥6.05

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2020 Results on Aug 21, 2020

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad